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genetic differences between inbred rodents in the labo-
ratory versus heterogeneous human populations in the
Replacement of defective or damaged body parts has
been a goal since ancient times. Today, advances in
surgical techniques and immunosuppressive therapies clinic, another important difference is the method and
circumstance of organ harvesting. Results for living re-have made tissue and organ transplantation a common-
place hospital procedure. Nevertheless, immunosup- lated donors have always been superior to those for
cadavers. This is likely due in large part to the extremepression is limited by the potential for opportunistic in-
fections and secondary tumors as well as specific drug physiologic stress to cadaveric organs. Baldwin and
colleagues review donor, transport, and recipient issuesside effects. Long-term outcomes are adversely im-
pacted by so-called “chronic rejection,” a fibrosing vas- related to cadaveric transplantation and the impact of
such stress on innate immunity, in particular, comple-cular complication that may be related to immunosup-
pression and at the very least is not responsive to current ment and natural killer cells. These additional effector
pathways impact the alloimmune response to trans-drug therapy.
The major barrier to successful organ transplantation plants and must be considered in the design of new
therapies and in instances where current therapies ap-is immunologic. Nonidentical recipients reject donor tis-
sues based upon recognition of major histocompatibility pear inadequate.
Emigration of leukocytes from the peripheral circula-antigens. Typing for these antigens has been a mainstay
of clinical transplantation. Recent progress in molecular tion into an allograft is an essential component of allo-
graft rejection. The past decade has witnessed an explo-biology has provided a host of tools to improve tissue
typing with the hope of improving transplant outcomes. sion in our understanding of the process of recruitment
of immune cells into a site of inflammation. Chemoat-Erlich and colleagues review progress in molecular diag-
noses of HLA molecules and their implications for solid tractant cytokines, chemokines, are a large family of
soluble molecules that attract and in many cases acti-organ and bone marrow transplantation. Polymerase
chain reaction (PCR)-based methods of HLA typing are vate immune cells. Therefore, chemokines and their re-
ceptors are potential targets for immune modulation.simple, rapid, highly informative, automatable, and can
be carried out at both intermediate and high levels of Nelson and Krensky review the current understanding
of the biology of chemokines and how this informationresolution. For solid organ transplantation, HLA match-
ing is important for kidney and heart transplantation, may be used to develop new therapies. Recent findings
that interruption of some chemokine pathways is ofbut not for liver. For bone marrow transplants, both
rejection and graft versus host disease are more fre- great benefit to organ allografts suggest that the role of
chemokines likely extends well beyond mere chemoat-quent across HLA mismatches. It is likely that the ulti-
mate effect of HLA mismatching depends on specific traction.
Libby and Pober address chronic rejection as the ma-HLA alleles and the clinical context. Progress in HLA
typing and bioinformation systems should help define jor cause of late graft loss. They discuss the immunologi-
cal mechanisms that underlie chronic rejection, howthe “rules” that govern clinical outcomes and allow iden-
tification of favorable or permissible HLA mismatches these mechanisms relate to other forms of graft injury,
and other lessons from experimental and/or clinicalin the future.
Presentation of antigens as peptides in the context studies of chronic rejection. They suggest that the pre-
cise immunologic mechanisms for chronic vascular re-of MHC (HLA) molecules by “professional” antigen-pre-
senting cells (APC) underlies all antigen-specific im- jection remain unclear and that new drugs and ap-
proaches will be required to overcome this remainingmune responses. Although monocyte/macrophage, B
lymphocyte, and other lineages that express MHC class hurdle to successful long-term allotransplantation.
Regulatory T cells may hold many of the keys to suc-II antigens can efficiently present peptide antigens to T
lymphocytes, the most potent APC are dendritic cells, cessful long-term organ transplantation. Although early
claims regarding the ability of “suppressor” CD81 T cellsfirst characterized by their distinctive cell shape. Den-
dritic cells are extremely potent inducers of the mixed to downregulate the host response to donor antigens
have proven difficult to substantiate, studies over thelymphocyte reactions and as such have been viewed
as major “foes” in transplant rejection, functioning as past decade clearly indicate that populations of CD41
“regulatory” cells are capable of dampening or eliminat-“passenger leukocytes” and self-APC that can present
antigen by both “direct” and “indirect” pathways. ing the antidonor immune response. Waldmann and
Cobbold review the characteristics of such regulatoryLechler and colleagues review dendritic cell biology,
pointing out that dendritic cells may function in promot- cells and their potential clinical utility and pose a series
of outstanding questions that must be answered for thising graft acceptance as well as rejection. This duality
of dendritic cell function has major implications for new controversial field to progress.
Apoptosis, programmed cell death, is a major area oftherapeutic approaches. For instance, dendritic cells
may be responsible for the activation of regulatory T investigation that has progressed rapidly in the past
decade. Strom, Turka, and colleagues highlight the im-cells capable of inducing and maintaining immune tol-
erance. portance of cell death in induction and maintenance of
immunologic tolerance. They review the results fromMany approaches to transplantation have enjoyed
greater success in animal models than in the clinic. Al- animal studies suggesting that the burden of antigen-
reactive T cells is important in the balance of immunitythough these differences may in large part be due to
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versus tolerance and present their model for the role of ing of antigen presentation, innate immunity, cell hom-
apoptotic cells in clinical transplantation. In order to ing, and chemoattraction have lead to novel diagnostic
achieve and maintain central tolerance, they suggest, and therapeutic approaches. Chronic rejection remains
long-lasting and massive deletion of donor-specific cells the major limitation to long-term graft survival, but new
must be achieved. In contrast, peripheral tolerance re- approaches aimed at blocking proliferative responses
quires more subtle therapies that permit ongoing apo- within blood vessels may prove beneficial. The ultimate
ptosis. Of note, long-lasting tolerance may require ele- goal of achieving immunologic tolerance may depend
ments of both: major clonal deletion followed by chronic on manipulation of antigen presentation, costimulation,
immunoregulation, including apoptosis. immune deviation, mixed chimerism, cell death, and/or
It has been known for many years that hematopoietic regulatory T cells. Other forefront approaches include
chimerism can lead to transplantation tolerance. Expo- cell regeneration/engineering and xenotransplantation.
sure of a developing immune system to donor antigen Although all of these approaches have their limitations,
results in education of the immune system to regard the progress has been immense and the impact of basic
donor as “self.” Sykes reviews recent experience with studies on potential new clinical therapies is likely near
induction of “mixed chimerism” in animal models and on the horizon. Soon the ultimate goal of routine, non-
the limited clinical experience to date. Such mixed chi- toxic, and permanent tissue and organ replacement may
merism can be achieved with non-myeloablative regi- be realized.
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graftment and sustained regeneration. In order to extend
the principles of stem cell biology and cell transplanta-
tion to more general tissue and organ regeneration,
Weissman and colleagues suggest that each system
must be evaluated as to whether the stem/progenitor/
progeny cell model holds for that tissue, whether such
cells are used only in embryonic development or if they
remain for adult regeneration, and whether the stem and
progenitor cells can be prospectively isolated. Assays
for clonogenic cells with readouts for both self-renewal
and differentiation have been developed. It is now clear
in many cases that tissue-specific stem cells exist and
that they can be therapeutically useful in transplantation
and selected autoimmune diseases. Additional tissue-
specific stem cells must be identified and their full devel-
opmental potential characterized at the clonal level.
Even if the extraordinary plasticity of tissue stem cells
in vitro does not reflect their in vivo potential, these
types of approaches will almost assuredly expand the
potential for new cell-based therapies.
Lastly, there is currently a great need for organ donors
with long waiting lists for all transplantable organ types.
Although it is possible that transplantation of cells, tis-
sues, or organs between disparate species may alleviate
this problem, there are daunting hurdles to overcome
before xenotransplantation is a clinical reality. Cascalho
and Platt summarize the current understanding of the
immunologic hurdles to xenotransplantation and sug-
gest how this information may be used to make xeno-
transplantation a clinical reality. Progress in overcoming
the humoral barrier to xenotransplantation and genetic
manipulation to date suggests that acute vascular rejec-
tion can be overcome, but, zoonoses and chronic rejec-
tion remain major concerns.
In summary, advances in our understanding of basic
immunology have resulted in a variety of preclinical
studies investigating new ways to overcome the limita-
tions of current clinical approaches to transplantation.
Improvements in tissue typing and a better understand-
